Literature DB >> 2205078

Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid.

S A Tsementzis1, W P Honan, S Nightingale, E R Hitchcock, C H Meyer.   

Abstract

Seventy-four patients with recent subarachnoid haemorrhage were randomly allocated to placebo or tranexamic acid treatment. Fibrinolytic activity in the blood and cerebrospinal fluid was assessed before treatment, one week later and two weeks later. The natural history of fibrinolysis following subarachnoid haemorrhage was obtained from analysis of the placebo group. Following subarachnoid haemorrhage, fibrin degradation products and plasminogen activity in the cerebrospinal fluid were elevated. Subsequently, fibrin degradation products in the cerebrospinal fluid fell progressively over the following 2 weeks. Changes in cerebrospinal fluid plasminogen activity correlated with those of blood plasminogen activity. Complications such as rebleeding, hydrocephalus or cerebral thrombosis could not be predicted from analysis of fibrinolytic activity. Tranexamic acid treatment resulted in a reduction in cerebrospinal fluid and blood plasminogen activity. The relevance of fibrinolysis in cerebrospinal fluid and blood to the management of subarachnoid haemorrhage is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205078     DOI: 10.1007/bf01407517

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  36 in total

1.  Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251.

Authors:  P Friberger; M Knös; S Gustavsson; L Aurell; G Claeson
Journal:  Haemostasis       Date:  1978

2.  The use of antifibrinolytic drugs to prevent early recurrent aneurysmal subarachnoid haemorrhage.

Authors:  D Tovi
Journal:  Acta Neurol Scand       Date:  1973       Impact factor: 3.209

3.  Streptokinase clot lysis time in patients with ruptured intracranial aneurysms.

Authors:  R Geronemus; D A Herz; K Shulman
Journal:  J Neurosurg       Date:  1974-04       Impact factor: 5.115

4.  Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.

Authors:  S A Tsementzis; E R Hitchcock; C H Meyer
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

5.  Fibrinolysis in subarachnoid haemorrhage.

Authors:  J R Gibbs; P O'Gorman
Journal:  Postgrad Med J       Date:  1967-12       Impact factor: 2.401

6.  Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage.

Authors:  D W Nibbelink; J C Torner; W G Henderson
Journal:  Stroke       Date:  1975 Nov-Dec       Impact factor: 7.914

Review 7.  Antifibrinolytic treatment in subarachnoid haemorrhage: present state.

Authors:  H Fodstad
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

8.  Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?

Authors:  R S Maurice-Williams; Y B Gordon; A Sykes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-02       Impact factor: 10.154

9.  Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial.

Authors:  H Fodstad; A Forssell; B Liliequist; M Schannong
Journal:  Neurosurgery       Date:  1981-02       Impact factor: 4.654

10.  Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial.

Authors:  W A Shucart; S K Hussain; P R Cooper
Journal:  J Neurosurg       Date:  1980-07       Impact factor: 5.115

View more
  8 in total

Review 1.  Brain ischemia in patients with intracranial hemorrhage: pathophysiological reasoning for aggressive diagnostic management.

Authors:  Daniel Naranjo; Michal Arkuszewski; Wojciech Rudzinski; Elias R Melhem; Jaroslaw Krejza
Journal:  Neuroradiol J       Date:  2013-12-18

2.  Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.

Authors:  S A Tsementzis; E R Hitchcock; C H Meyer
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

Review 3.  Tranexamic acid: a review of its use in surgery and other indications.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 4.  Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage.

Authors:  Mark Chwajol; Robert M Starke; Grace H Kim; Stephan A Mayer; E Sander Connolly
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

5.  Endogenous fibrinolysis in neonatal cerebrospinal fluid.

Authors:  A Whitelaw
Journal:  Eur J Pediatr       Date:  1993-11       Impact factor: 3.183

Review 6.  Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.

Authors:  Merih I Baharoglu; Menno R Germans; Gabriel J E Rinkel; Ale Algra; Marinus Vermeulen; Jan van Gijn; Yvo B W E M Roos
Journal:  Cochrane Database Syst Rev       Date:  2013-08-30

7.  Safety and Efficacy of Tranexamic Acid in Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Junwei Ren; Dongxi Qian; Jiaming Wu; Lingyan Ni; Wei Qian; Guozheng Zhao; Chuanjun Huang; Xing Liu; Yu Zou; Weikang Xing
Journal:  Front Neurol       Date:  2022-01-24       Impact factor: 4.003

8.  Transient Obstructive Hydrocephalus due to Intraventricular Hemorrhage: A Case Report and Review of Literature.

Authors:  Eriks A Lusis; Ananth K Vellimana; Wilson Z Ray; Michael R Chicoine; Sarah C Jost
Journal:  J Clin Neurol       Date:  2013-07-01       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.